Status:
ACTIVE_NOT_RECRUITING
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
Lead Sponsor:
AstraZeneca
Conditions:
Solid Tumors
Eligibility:
All Genders
18-130 years
Phase:
PHASE1
Brief Summary
Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.
Eligibility Criteria
Inclusion
- Written informed consent
- Prostate cancer), which is refractory to standard therapies or for which no standard therapy exists.
- Estimated life expectancy of at least 8 weeks
- WHO performance status (PS) 0-2.
Exclusion
- Unstable brain/meningeal metastases
- Biochemistry/haematology results outside of required ranges
- History of significant GI impairment
- Inadequate bone marrow reserve
Key Trial Info
Start Date :
September 9 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00750841
Start Date
September 9 2008
End Date
December 31 2025
Last Update
November 24 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
2
Research Site
Montreal, Quebec, Canada, H3T 1E2
3
Research Site
Dundee, United Kingdom, DD1 9SY
4
Research Site
Glasgow, United Kingdom, G12 0YN